• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Precision Optics Corporation Inc.

    4/9/25 4:16:04 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email
    DEFA14A 1 poci_defa14a.htm FORM DEFA 14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant   þ

    Filed by a Party other than the Registrant   o

     

    Check the appropriate box:

     

    o  Preliminary Proxy Statement

    o  Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))

    o  Definitive Proxy Statement

    þ  Definitive Additional Materials

    o  Soliciting Material under Rule 14a-12

     

    Precision Optics Corporation, Inc.
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    þ  No fee required

    o  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

      (1) Title of each class of securities to which transaction applies:

     

      (2) Aggregate number of securities to which transaction applies:

     

      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

     

      (4) Proposed maximum aggregate value of transaction:

     

      (5) Total fee paid:

     

    o  Fee paid previously with preliminary materials.

     

    o  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

     

      (1) Amount Previously Paid:

     

      (2) Form, Schedule or Registration Statement No.:

     

      (3) Filing Party:

     

      (4) Date Filed:

     

     

     

       

     

     

     

     

    Your Vote Counts! PRECISION OPTICS CORPORATION, INC. 22 EAST BROADWAY GARDNER, MA 01440 PRECISION OPTICS CORPORATION, INC. 2024 Annual Meeting Vote by May 19, 2025 11:59 PM ET Vote in Person at the Meeting* May 20, 2025 10:00 am EDT DoubleTree By Hilton, Leominster 99 Erdman Way, Leominster, MA 01453 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V69604 - P31932 You invested in PRECISION OPTICS CORPORATION, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 20, 2025. Get informed before you vote View the proxy statement and annual report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 6, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

       

     

     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V69605 - P31932 For 1. Election of Directors Nominees: 1a. Peter H. Woodward For 1b. Andrew J. Miclot For 1c. Buell G. Duncan For 1d. Joseph P. Pellegrino, Jr. For 1e. Joseph N. Forkey For 2. To consider and vote on whether to approve, on an advisory basis, the compensation paid to our Named Executive Officers for the year ending June 30, 2024 For 3. To ratify the appointment of Stowe & Degon LLC as our independent registered public accounting firm for the year ending June 30, 2025 Voting Items Board Recommends

       

     

     

     

     

    Get the next $POCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:31 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:30 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:33 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

      SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      11/13/24 5:53:45 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Precision Optics Corporation Inc.

      SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      5/17/24 5:03:18 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Financials

    Live finance-specific insights

    See more
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Second Quarter of Fiscal Year 2025 Conference Call for February 13, 2025

      GARDNER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, February 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, February 13, 2025, at 5:00 p.m. ET. Call-in Information: Inter

      2/11/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024

      GARDNER, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2025 financial results on Thursday, November 14, 2024, at 5:00pm ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 14, 2024, followed by the conference call. Conference Call Details Date and Time: Thursday, November 14, 2024, at 5:00pm ET Call-in Information: Interested pa

      11/11/24 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    SEC Filings

    See more
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/23/25 4:40:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/20/25 4:15:10 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/19/25 4:30:09 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results

      GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its third quarter fiscal year 2025 for the period ended March 31, 2025. Q3 2025 Financial Highlights (3 Months Ended March 31, 2025): Revenue was $4.2 million compared to $5.2 million in the same quarter of the previous fiscal year and compared to $4.5 million in the most recent sequential quarter.Production revenue was $3.3 million compared to $3.0 million in the same quarter of the previous fiscal year and compared to $

      5/15/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

      GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapCl

      4/21/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

      GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

      3/4/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

      GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

      7/8/24 9:00:00 AM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woodward Peter H exercised 30,000 shares at a strike of $2.19 and covered exercise/tax liability with 14,536 shares (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      5/20/25 4:15:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Pellegrino Joseph P Jr

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:17:04 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman was granted 20,000 shares, increasing direct ownership by 16% to 142,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:15:13 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care